Drugs

Switzerland-based Novartis released results of what it called a next-generation treatment. A study of its experimental drug in 12 African countries found it works well against the mosquito-borne parasite that causes malaria and seems to block spread.

A new review notes using antihistamines and corticosteroids first may delay giving the only effective treatment.

A recent study integrated pharmacovigilance data with nationwide health claims to reveal four drugs with the greatest elevated risk of maculopathy, potentially leading to visual impairment.

Researchers behind the study published in the New England Journal of Medicine say the discovery could potentially alter the clinical care of millions of people around the world.

Study finds it is just as effective as ketamine at blocking muscarinic receptors, which are responsible for involuntary bladder contractions.

Taken to improve sleep quality, the drugs actually lead to a decline in certain important parameters, particularly for memory and cognitive health, in seniors.

Study integrates pharmacovigilance data with nationwide health claims to reveal overlooked risk of maculopathy with certain systemic drugs.

Amiodarone is an antiarrhythmic drug used to treat various ventricular and atrial tachyarrhythmias. Although it is an effective drug, amiodarone is associated with many different adverse effects, including pulmonary, thyroid, ocular and liver toxicity.